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Abstract. X-linked muscular dystrophy is caused by primary 
abnormalities in the Dmd gene and is characterized by the 
almost complete loss of the membrane cytoskeletal protein 
dystrophin, which triggers sarcolemmal instability, abnormal 
calcium homeostasis, increased proteolysis and impaired exci-
tation-contraction coupling. In addition to progressive necrosis, 
crucial secondary pathologies are represented by myofibrosis 
and the invasion of immune cells in damaged muscle fibres. In 
order to determine whether these substantial changes within 
the skeletal musculature are reflected by an altered rate of 
protein release into the circulatory system or other plasma 
fluctuations, we used label‑free mass spectrometry to charac-
terize serum from the mdx‑4cv model of Duchenne muscular 
dystrophy. Comparative proteomics revealed a large number of 
increased vs. decreased protein species in mdx‑4cv serum. A 
serum component with greatly elevated levels was identified as 
the inflammation‑inducible plasma marker haptoglobin. This 
acute phase response protein is usually secreted in relation 
to tissue damage and sterile inflammation. Both immunoblot 
analyses and enzyme‑linked immunosorbent assays confirmed 
the increased concentration of haptoglobin in crude mdx‑4cv 
serum. This suggests that haptoglobin, in conjunction with 
other altered serum proteins, represents a novel diagnostic, 
prognostic and/or therapy-monitoring biomarker candidate 
to evaluate the inflammatory response in the mdx‑4cv animal 
model of dystrophinopathy.
Introduction
Duchenne muscular dystrophy is a devastating muscle 
wasting disease of early childhood (1) and the most frequently 
inherited neuromuscular disorder (2). It has an X-linked 
mode of inheritance and is primarily caused by abnormalities 
in the Dmd gene, which trigger the almost complete 
absence of the membrane cytoskeletal protein dystrophin of 
427 kDa (3). The loss of dystrophin results in a significant 
reduction of dystrophin-associated glycoproteins, which in 
turn impairs the linkage between the extracellular matrix 
component laminin and the actin membrane cytoskeleton (4). 
In addition to destabilizing the fibre periphery and thereby 
making muscle cells more susceptible to micro-rupturing 
during excitation-contraction-relaxation cycles (5), a variety 
of secondary changes play a key role in the molecular 
pathogenesis of X-linked muscular dystrophy (6). This includes 
reactive myofibrosis resulting in tissue scarring and loss of 
fibre elasticity, abnormal calcium regulation and increased 
proteolytic degradation, impaired cellular signalling and 
disturbed excitation-contraction coupling, as well as sterile 
inflammation of dystrophin-deficient muscle tissue (7-10). 
Therefore, the immune system appears to play a critical role in 
X-linked muscular dystrophy (11-14). It is debatable whether 
the inflammatory pathology of dystrophic muscles is based on 
a reactive and relatively non‑specific invasion of immune cells 
in damaged muscle fibres or represents a separate mechanism 
that promotes fibre degeneration independent of sarcolemmal 
destabilisation (15-17). Thus, although dystrophinopathies 
are triggered by a single gene defect, the pathophysiological 
consequences and adaptive responses of dystrophic muscles 
are highly complex.
In the pre-proteomic era, a variety of muscle-derived 
protein markers have been established for general diagnostic 
purposes. Serum markers with an association to tissue damage 
and muscular injury include creatine kinase, pyruvate kinase, 
hemopexin, adenylate kinase, carbonic anhydrase and lactate 
dehydrogenase (18-22). However, the concentration of some of 
these serum markers vary considerably in healthy individuals, 
lack a high degree of specificity and/or exhibit inconsistencies 
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in their concentration changes during acute vs. chronic 
disease stages. This potential lack of diagnostic reliability 
and limited robustness restricts the clinical usefulness of 
many general protein biomarkers of skeletal muscle damage 
for accurate sample screening, prognosis or clinical outcome 
measures. More specific serum proteins that exhibit elevated 
levels in Duchenne patients seem to be the tissue inhibitors 
of metalloproteinase-1, transforming growth factor TGF-β1 
and the matrix metalloproteinase MMP-9 (23-26). In contrast 
to traditional biochemical studies that usually focus on the 
characterization of a restricted number of specific candidate 
molecules, large-scale biochemical approaches promise to 
gain new global insights into the molecular and cellular 
mechanisms of muscular dystrophy. Mass spectrometry-based 
proteomics is highly suitable to improve our general 
understanding of complex changes in dystrophinopathies (27). 
Systems biological methods promise to determine potential 
pathophysiological hierarchies and interconnectivities 
between differing secondary mechanisms within muscle 
tissues that are downstream of the pathobiochemical 
collapse of the dystrophin-glycoprotein complex (28). Most 
importantly, the systematic proteomic identification of new 
serum biomarkers is crucial for the improved diagnostic and 
prognostic evaluation of Duchenne muscular dystrophy and 
animal models of dystrophin deficiency (29).
In the field of muscular dystrophy research, the systematic 
screening of body fluids from Duchenne patients and 
established animal models of dystrophinopathies using 
proteomic technology has recently established a variety of new 
biomarker candidates, including fibronectin, the coagulation 
factor XIIIa, titin, various myosin light chain isoforms, 
myomesin-3, filamin-C, lysosomal-associated membrane 
protein LAMP1 and its accompanying vesicle proteins, aldolase, 
phosphoglycerate mutase, enolase, glycogen phosphorylase, 
fatty acid-binding protein, myoglobin, cytochrome c, malate 
dehydrogenase, fibrinogen, parvalbumin, electron transfer 
flavoprotein A, troponin, Ca2+/calmodulin-dependent protein 
kinase Camk2b, metalloproteinase Adamts5, troponin-1, 
myoglobin and heat-shock protein HSPA1A (30-39). In 
analogy to these studies and to establish new biomarker 
candidates for the improved evaluation of animal models of 
dystrophinopathy, we analysed serum from the dystrophic 
mdx‑4cv mouse (40). The mdx‑4cv model exhibits 
substantially less revertant dystrophin-positive fibres than 
the conventional mdx mouse (41), which is advantageous for 
outcome measurements in experimental treatment studies, 
such as exon-skipping therapy (42). Comparative proteomics 
of mdx‑4cv vs. wild‑type serum established a significantly 
increased concentration of the inflammation-inducible 
plasma marker haptoglobin (43). The elevated levels of this 
acute phase response protein agree with skeletal muscle 
damage and sterile inflammation in muscular dystrophy. This 
establishes haptoglobin as a novel biomarker candidate of the 
inflammatory response in dystrophinopathy.
Materials and methods
Materials. Immunodepletion of serum samples was carried out 
with Proteome Purify 2 Mouse Serum Protein Immunodepletion 
Resin (R&D Systems, Inc., Minneapolis, MN, USA). 
Ultrapure acrylamide stock solutions for gel electrophoresis 
were purchased from National Diagnostics (Atlanta, GA, 
USA). Invitrogen (Carlsbad, CA, USA) supplied Whatman 
nitrocellulose transfer membranes. The chemiluminescence 
substrate and protease inhibitors were obtained from Roche 
Diagnostics GmbH (Mannheim, Germany). Superfrost Plus 
positively-charged microscope slides were obtained from 
Menzel Glaser (Braunschweig, Germany). Sequencing grade 
modified trypsin and Lys‑C were purchased from Promega Corp. 
(Madison, WI, USA). Pierce C18 Spin Columns were obtained 
from Thermo Fisher Scientific (Dublin, Ireland). Primary 
antibodies were purchased from Abcam (Cambridge, UK) 
(ab131236 to haptoglobin, ab14225-200 to albumin, ab52488 
to lactate dehydrogenase, ab9033-1 to transferrin, ab15277 
to dystrophin and ab11427 to parvalbumin) and Santa Cruz 
Biotechnology, Santa Cruz, CA, USA (sc‑25607 to myoglobin). 
Chemicon International, Inc. (Temecula, CA, USA) provided 
peroxidase-conjugated secondary antibodies. Enzyme-linked 
immunosorbent assay assays (ELISA) were purchased from 
Abcam (ab157714 to haptoglobin and ab157711 to complement 
C3) and R&D Systems (FABP‑1/L‑FABP). Normal goat serum 
and Cy3-conjugated antibodies were obtained from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 
The embedding medium Fluoromount-G was obtained from 
Southern Biotech (Birmingham, AL, USA). A variety of other 
general chemicals, including bis-benzimide Hoechst-33342, 
were of analytical grade and obtained from Sigma Chemical 
Company (Dorset, UK).
Dystrophic mdx‑4cv animal model of Duchenne muscular 
dystrophy. In order to investigate the serum proteome and 
identify potential biomarkers of dystrophinopathy, the mdx‑4cv 
animal model was employed in the present study. This mouse 
model has been generated using N-ethylnitrosourea to induce 
a premature stop codon in exon 53 of the Dmd gene (44). 
The mdx‑4cv model has 10-fold fewer dystrophin-positive 
revertant fibres (41) than the conventional mdx mouse (45) and 
thus its serum proteome may be more representative of the 
human condition. Mice were bred in the Bioresource Unit of 
the University of Bonn under standard conditions (46) with 
the authorization by the District Veterinary Office in Bonn, 
Germany. Tissue and organ harvesting was regularly reported 
to the District Veterinary Office. Serum and muscle samples 
from 6-month-old mdx‑4cv and age-matched wild-type 
C57BL6 mice were obtained after sacrificing the animals by 
cervical dislocation. Samples were immediately quick-frozen 
in liquid nitrogen and stored at ‑80˚C prior to usage. Samples 
were transported to Maynooth University on dry ice in accor-
dance with the Department of Agriculture (animal by-product 
register number 2016/16 to the Department of Biology, 
National University of Ireland, Maynooth).
Immunodepletion of mouse serum samples. One of the 
main challenges with the proteomic profiling of biofluids, 
particularly for serum and plasma, is the wide dynamic range 
of protein expression (47). Since highly abundant proteins 
such as albumin and IgG constitute the majority of plasma 
proteins, and this seriously interferes with the detection of 
low-copy-number proteins by mass spectrometry (48), many 
profiling studies use immunodepletion strategies to achieve an 
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enriched pool of low-abundance proteins. We here used the 
Proteome Purify 2 Mouse Serum Protein Immunodepletion 
Resin to remove the highly abundant proteins albumin and 
IgG from the murine serum samples. In summary, 10 µl of 
serum was added to a micro-centrifuge tube containing 
1 ml of immunodepletion resin. The tubes were placed on a 
rotary shaker for 1 h at room temperature. After the incuba-
tion period, the mixture was added to the upper chamber of 
a Spin‑X filter unit (centrifuge tube with a 0.22‑µm cellulose 
acetate membrane) and centrifuged for 2 min at 2,000 x g. The 
filtrate was collected and used for further analysis.
Sample preparation for mass spectrometry. Immunodepleted 
serum samples were acetone precipitated and the resulting 
pellets were re-suspended in label-free solubilisation buffer 
(6 M urea, 2 M thiourea, 10 mM Tris, pH 8.0 in LC/MS 
grade water). Protein concentrations were determined by 
the Bradford assay system (49) and sample volumes were 
equalised with label-free solubilisation buffer. Samples were 
reduced for 30 min at 37˚C with 10 mM dithiothreitol and 
alkylated with 25 mM iodoacetamide in 50 mM ammonium 
bicarbonate for 20 min in the dark at room temperature (50). 
To limit alkylation of trypsin by any remaining unreacted 
iodoacetamide, samples were reduced with a further 10 mM 
dithiothreitol for 15 min in the dark at room temperature. 
Proteolytic digestion of serum proteins to their constitutive 
peptides was carried out in two steps. Firstly samples were 
digested with sequencing grade Lys-C at a ratio of 1:100 
(protease:protein) for 4 h at 37˚C, followed by dilution with 
four times the initial sample volume in 50 mM ammonium 
bicarbonate. Secondly, samples were digested with 
sequencing-grade trypsin at a ratio of 1:25 (protease:protein) 
overnight at 37˚C (51). Samples were acidified with 2% 
trifluoroacetic acid (TFA) in 20% acetonitrile (ACN) [3:1 
(v/v) dilution]. Peptide suspensions were purified using Pierce 
C18 Spin Columns, dried through vacuum centrifugation 
and suspended in loading buffer consisting of 2% ACN and 
0.05% TFA in LC‑MS grade water. Samples were vortexed 
and sonicated to ensure an even suspension of peptides prior 
to mass spectrometric analysis.
Label‑free liquid chromatography mass spectrometric 
analysis. The label-free liquid chromatography mass spectro-
metric (LC-MS/MS) analysis of mdx‑4cv vs. wild-type serum 
samples was carried out using an Ultimate 3000 NanoLC 
system (Dionex Corporation, Sunnyvale, CA, USA) coupled 
to a Q‑Exactive mass spectrometer (Thermo Fisher Scientific). 
Peptide mixtures (5 µl, corresponding to 1 µg protein) were 
loaded by an autosampler onto a C18 trap column (C18 
PepMap, 300 µm id x 5 mm, 5 µm particle size, 100 A pore 
size; Thermo Fisher Scientific). The trap column was switched 
on‑line with an analytical Biobasic C18 Picofrit column (C18 
PepMap, 75 µm id x 50 cm, 2 µm particle size, 100 A pore size; 
Dionex Corporation). Serum-derived peptides were eluted 
using the following gradient (solvent A: 80% (v/v) ACN and 
0.1% (v/v) formic acid in LC‑MS grade water): 5% solvent A 
for 120 min, 45% solvent A for 2.5 min, 90% solvent A for 
9 min and 3% solvent A for 43 min (52). The column flow rate 
was set to 0.3 µl/min. Data were acquired with Xcalibur soft-
ware (Thermo Fisher Scientific). The Q‑Exactive was operated 
in positive and data-dependent mode and was externally cali-
brated. Survey MS scans were conducted in the 300-1,700 m/z 
range with a resolution of 140,000 (m/z 200) and lock mass set 
to 445.12003. Collision-induced dissociation fragmentation 
was carried out with the 15 most intense ions per scan and at 
17,500 resolution. Within 30 sec, a dynamic exclusion window 
was applied. An isolation window of 2 m/z and one microscan 
were used to collect suitable tandem mass spectra.
Quantitative proteomic profiling by label‑free LC‑MS/MS 
analysis. Quantitative analysis of the raw data generated from 
LC-MS/MS was conducted with Progenesis QI for Proteomics 
software (version 3.1; Nonlinear Dynamics, Ltd., Newcastle 
upon Tyne, UK). A reference run was selected based on the 
highest number of peptide ions and the retention times of 
all the other runs were aligned to this reference run. This 
accounted for any drift in LC retention time, thus giving an 
adjusted retention time for all runs in the analysis (53). The 
data were filtered using the criteria listed below and were then 
exported as a Mascot generic file to Proteome Discoverer 2.0 
(Thermo Scientific); i) peptide features with ANOVA ≤0.05 
between experimental groups, ii) mass peaks with charge 
states from +1 to +5 and iii) greater than one isotope per peptide. 
The exported MS/MS spectra from Progenesis software were 
used for peptide identification using Proteome Discoverer 2.0 
against Mascot (version 2.3) and Sequest HT and searched 
against the UniProtKB‑SwissProt database (taxonomy: 
Mus musculus). The following search parameters were used 
for protein identification: i) peptide mass tolerance set to 
10 ppm, ii) MS/MS mass tolerance set to 0.02 Da, iii) up to 
two missed cleavages were allowed, iv) carbamidomethylation 
set as a fixed modification and v) methionine oxidation set 
as a variable modification (54). For re-importation back 
into Progenesis LC-MS software for further analysis, only 
peptides classified as high confidence peptides and with ion 
scores of 40.00 or more (from Mascot) and/or XCorr scores 
>1.5 for singly charged ions, >2.0 for doubly charged ions 
and >3.0 for triply charged ions (Sequest HT, Thermo Fisher 
Scientific) were selected. The following criteria were applied 
to assign a protein as properly identified and with differential 
abundance: i) an ANOVA score between experimental groups 
of ≤0.05, and ii) proteins with ≥2 peptides matched (55). The 
PANTHER database of protein families (http://pantherdb.org; 
version 10.0) was used to group proteins based on their protein 
class (56).
Immunoblot analysis. Immunoblotting using a panel of select 
antibodies was used for the independent verification of the 
proteomic findings. Immunoblotting was performed using 
routine conditions as previously described in detail (57). 
Briefly, crude serum samples were separated by gel electro-
phoresis using 10% 1D polyacrylamide gels, followed by wet 
transfer to nitrocellulose membranes at 100 V for 70 min at 4˚C 
in a Trans‑Blot cell from Bio‑Rad Laboratories (Richmond, 
CA, USA). Transfer efficiency was assessed using Ponceau 
reversible stain and membranes were then blocked for 1 h at 
room temperature using a milk protein solution [2.5% (w/v) 
fat-free milk powder in phosphate buffered saline] (58). 
Membranes were incubated with appropriately diluted primary 
antibodies overnight at 4˚C with gentle agitation. Membranes 
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were then washed with the milk protein solution twice for 
10 min and incubated with peroxidase-conjugated secondary 
antibodies for 1.5 h at room temperature with gentle agitation. 
Following a series of washing steps with the milk protein solu-
tion and phosphate-buffered saline, antibody-labelled protein 
bands were visualised using enhanced chemiluminescence. 
Densitometric scanning and statistical analysis of immunob-
lots were performed using a HP PSC-2355 scanner and ImageJ 
software [National Institutes of Health (NIH), Bethesda, 
MA, USA] along with Graph-Pad Prism software (San Diego, 
CA, USA), in which a P<0.05 was deemed to be statistically 
significant.
ELISA. ELISA was employed to independently verify key 
findings from the mass spectrometric analysis. Crude serum 
samples were screened using quantitative sandwich enzyme 
immunoassays to haptoglobin, FABP‑1 and complement C3. 
Appropriately diluted serum samples (1:400 for FABP‑1, 1:1,000 
for haptoglobin, and 1:30,000 for complement C3 assay) were 
added to antibody-coated microtiter wells and were incubated 
at room temperature for 20 min (for complement C and hapto-
globin) or 2 h (for FABP‑1). After the incubation period, wells 
were washed and a peroxidase-labelled secondary detector 
antibody was added. After incubation at room temperature 
for 20 min in the dark, tetramethylbenzidine chromogen 
substrate was added. The reaction was stopped after 10 min 
(for complement C and haptoglobin) or 30 min (for FABP‑1) 
and absorbance was measured at λ=450 nm on a microplate 
reader (33). The quantity of protein in the test samples was 
interpolated from the standard curve and was corrected for 
sample dilution. All ELISA assays were carried out with crude 
serum from wild-type (n=5) and mdx‑4cv (n=8 for comple-
ment C3; n=7 for haptoglobin and FABP‑1) mice. All test 
samples were assayed in triplicate. The intra‑plate % CV was 
calculated and was found to be less than 10% for all assays. 
Statistical ROC (receiver operating characteristics) analyses 
were performed using MedCalc for Windows, version 16.8 
(MedCalc Software BVBA, Ostend, Belgium) to determine 
representaive AUC values for individual ELISA assays.
Immunofluorescence microscopy. To establish the mutant and 
dystrophic status of mdx‑4cv mice at the age of 6 months, 
deficiency in the dystrophin protein isoform Dp427 and 
histological skeletal muscle changes were established by 
immunofluorescence microscopy and histological analysis, 
respectively (59). Dystrophic mdx‑4cv and wild-type gastroc‑
nemius muscles were freshly dissected and then quick-frozen 
in liquid nitrogen. Histochemical staining was carried out with 
routine haematoxylin and eosin staining. Cryo-sectioning was 
employed to generate 10 µm muscle tissue sections, which 
were placed on Superfrost Plus positively-charged microscope 
slides. Skeletal muscle cryosections were then boiled to 
reduce background staining (60) and permeabilized in 0.1% 
(v/v) Triton X-100 in phosphate-buffered saline for 30 min 
at room temperature (61). Tissue sections were blocked in 
20% (v/v) normal goat serum in phosphate‑buffered saline 
for 30 min and incubated overnight at 4˚C with an appro-
priately diluted antibody to dystrophin. Following a careful 
washing step, skeletal muscle sections were incubated with 
Cy3-conjugated anti-IgG antibodies (1:200) for 30 min at 
room temperature. Primary antibodies were omitted for 
control staining. Antibody-labelled skeletal muscle sections 
were embedded in Fluoromount-G medium and viewed under 
a Zeiss Axioskop 2 epi‑fluorescence microscope equipped 
with a digital Zeiss AxioCam HRc camera (Carl Zeiss Jena 
GmbH, Jena, Germany).
Results
In order to evaluate whether the dystrophic phenotype 
of the mdx‑4cv mouse is reflected by an altered rate of 
protein release into the circulatory system or other plasma 
fluctuations, potential changes in the mdx‑4cv serum proteome 
were determined by label-free mass spectrometry. Key 
findings from the proteomic profiling of serum samples were 
verified by comparative immunoblotting and enzyme‑linked 
immunosorbent assays.
Dystrophic mdx‑4cv model of dystrophinopathy. Prior to 
the proteomic profiling of serum samples, the mutant and 
dystrophic status of the 6-month-old mdx‑4cv animal model 
of Duchenne muscular dystrophy was established using 
immunofluorescence microscopy and histological assess-
ment. Fig. 1 clearly demonstrates the dystrophic phenotype 
of the mdx‑4cv gastrocnemius muscle (45). In contrast to 
the relatively regular cell shape and peripheral nucleation in 
wild-type (wt) mouse muscle (Fig. 1A), transverse sections of 
the mdx‑4cv mouse muscle showed central nucleation and the 
infiltration of immune cells in areas of fibre damage (Fig. 1B). 
The peripheral labelling of dystrophin isoform Dp427 in wt 
muscle by immunofluorescence microscopy (Fig. 1C) was in 
stark contrast to the lack of dystrophin staining in mdx‑4cv 
mutant muscle (Fig. 1D).
Pre‑fractionation of mdx‑4cv serum. Protein depletion, 
pre-fractionation and post-fractionation are routinely 
employed methods in proteomic studies of body fluids that 
exhibit a complex proteome with the presence of a few highly 
abundant proteins. These protein species may mask the detec-
tion of low-copy-number protein species. Albumin and IgG 
molecules are major classes of abundant plasma proteins and 
may therefore interfere with the detection of low-abundance 
proteins in comparative proteomic studies (48). We therefore 
employed an immunodepletion strategy to reduce sample 
complexity and enrich the starting material in serum proteins 
with a relatively low concentration (62).
In general, immunodepletion is a widely employed and 
internationally accepted approach for studying complex 
biofluids (63). This protein depletion technique decisively 
reduces the problem of dynamic range in both LC-MS/MS and 
gel-based biomarker studies (64-68). However, albumin and 
other major plasma proteins have been shown to bind a diverse 
range of minor peptides and proteins and thus the albumin- 
and IgG-depleted serum proteome may be slightly altered in 
relation to the composition of select protein species (69-71), in 
what is generally referred to as the ‘carrier-and-cargo’ effect 
of the albuminome.
Thus, although albumin/IgG depletion can result in a 
concomitant decrease in certain low-molecular-mass proteins 
due to their biological interactions with albumin or IgG 
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molecules, the analytical advantages of reducing sample 
complexity outweigh this issue (62). Fig. 2 illustrates the 
successful depletion of albumin and IgG from the crude 
serum samples derived from dystrophic mdx‑4cv mice 
and wild-type animals. A representative silver-stained gel 
confirmed the alteration in the overall protein composition of 
crude serum vs. immuno-depleted serum (Fig. 2A). In contrast 
to transferrin, for which the abundance was not highly altered 
following pre‑fractionation (Fig. 2B), the amounts of albumin, 
IgG heavy chain and IgG light chain were markedly decreased 
in the immuno-depleted fractions (Fig. 2C and D).
Proteomic profiling of 6‑month‑old mdx‑4cv serum. The 
proteomic profiling approach used in the present study 
is summarized in the f low chart of Fig. 3. Following 
pre-fractionation, the albumin/IgG-depleted serum from 
wild-type vs. dystrophic mdx‑4cv mice was analysed by 
comparative label-free mass spectrometry to establish 
the serum signature of dystrophinopathy. The proteomic 
survey of 2 technical repeats each of 4 biological samples 
identified 461 changed serum protein species consisting 
of 360 increased and 101 decreased proteins in mdx‑4cv serum. 
As an illustrative example, the crucial proteomic identification 
and mass spectrometric fingerprint of the acute response 
phase protein haptoglobin (Q61646) is shown in Fig. 3. The 
independent verification of key proteomic findings was carried 
out by immunoblotting and enzyme-linked immunosorbent 
assays, as outlined below. Identified proteins with a high degree 
Figure 1. Histological and immunofluorescence microscopic analysis of 6‑month‑old mdx‑4cv mouse gastrocnemius muscle. Shown are histological staining 
with haematoxylin and eosin (A and B) and immunofluorescence labelling with an antibody to dystrophin isoform Dp427 (C and D) of muscle sections from 
wild-type (A and C) vs. mdx‑4cv (B and D) mouse gastrocnemius muscle. Scale bars represent 10 and 40 µm in panels (A and B) and (C and D), respectively.
Figure 2. Immunoblot analysis of the pre-fractionation immunodepletion of mdx‑4cv mouse serum. Prior to the proteomic screening of mdx‑4cv serum, 
immunodepletion was used to reduce sample complexity and enrich the starting material in serum proteins with a relatively low concentration. Shown is a 
silver‑stained gel (A) and corresponding immunoblots labelled with antibodies to transferrin (B), albumin (C) and IgG (D). Lanes 1 to 4 represent 6‑month‑old 
wild-type vs. mdx‑4cv crude serum (CS) and immuno-depleted serum (ID), respectively. Molecular mass standards are marked at the left of the panels.
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of increase vs. decrease are listed in Tables I-III, respectively. 
The tables list information in relation to accession number, 
protein name, number of unique peptides, confidence score 
and fold change.
The most  markedly elevated levels  included 
Na+/H+ exchange regulatory cofactor NHE-RF1, sedo-
heptulokinase, α‑1B‑glycoprotein, heterogeneous nuclear 
ribonucleoprotein A/B and A3, nucleolin, peptidyl‑prolyl 
cis‑trans isomerase FKBP3, calretinin, α-1-acid glycoprotein 
2, hypoxanthine-guanine phosphoribosyl-transferase, hapto-
globin, cytoplasmic threonine‑tRNA ligase, tubulin‑specific 
chaperone A, lambda-crystallin homolog, myomesin-3, von 
Willebrand factor A domain-containing protein 5A, serum 
Table I. List of increased proteins in 6-month-old mdx‑4cv mouse serum vs. age-matched wild-type mouse serum as determined 
by label-free mass spectrometry.
Accession no. Protein name Unique peptides Confidence score    Fold change
P70441 Na(+)/H(+) exchange regulatory cofactor NHE-RF1  2 128.77 384.8
Q9D5J6 Sedoheptulokinase  3 181.59 213.1
Q19LI2 α‑1B‑glycoprotein  3 201.11 199.9
Q99020 Heterogeneous nuclear ribonucleoprotein A/B  2 120.87 131.4
P09405 Nucleolin  2 66.85 104.3
Q62446 Peptidyl-prolyl cis‑trans isomerase FKBP3  2 69.16 89.1
Q8BG05 Heterogeneous nuclear ribonucleoprotein A3  2 132.17 72.8
Q08331 Calretinin  5 174.3 59.9
P07361 α-1-acid glycoprotein 2  2 101.47 56.8
P00493 Hypoxanthine-guanine phosphoribosyltransferase  2 73.54 53.3
Q61646 Haptoglobin  14 826.52 50.3
Q9D0R2 Threonine-tRNA ligase, cytoplasmic  5 187.79 48.4
P48428 Tubulin‑specific chaperone A  2 59.15 46.8
Q99KP3 Lambda-crystallin homolog  3 173.73 43.3
A2ABU4 Myomesin‑3  9 588.37 38.6
Q99KC8 von Willebrand factor A domain-containing protein 5A  2 41.66 37.2
P05366 Serum amyloid A-1 protein  2 135.98 36.9
Q8VC12 Urocanate hydratase  10 751.33 36.9
P47199 Quinone oxidoreductase  4 206.42 36.8
Q91X52 L-xylulose reductase  2 99.38 32.8
Q8VCX1 3-oxo-5-β-steroid 4-dehydrogenase  5 177.09 31.2
Q9WTP6 Adenylate kinase 2, mitochondrial  2 67.03 31.2
A3KMP2 Tetratricopeptide repeat protein 38  4 177.89 30.6
Q5SX40 Myosin-1  62 4670.12 30.3
A2ASS6 Titin  88 4357.28 30.2
P99027 60S acidic ribosomal protein P2  2 162.5 30.1
Q8VCT4 Carboxylesterase 1D  5 114.1 26.8
P53026 60S ribosomal protein L10a  2 97.35 26.5
P68040 Guanine nucleotide-binding protein subunit β-2-like 1  2 48.55 25.6
Q9QXE0 2-Hydroxyacyl-CoA lyase 1  4 252.9 24.5
Figure 3. Overview of the proteomic strategy to determine global changes in 
the protein constellation of mdx‑4cv mouse serum. The flow chart outlines 
the comparative analysis of wild-type vs. mdx‑4cv serum samples and shows 
the mass spectrometric fingerprint of the acute phase plasma protein hapto-
globin as a major finding of this proteomic study
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amyloid A-1 protein, urocanate hydratase, quinone oxidoreduc-
tase, L-xylulose reductase, 3-oxo-5-β-steroid 4-dehydrogenase, 
mitochondrial adenylate kinase 2, tetratricopeptide repeat 
protein 38, myosin‑1 and titin. A very interesting finding was 
the identification of increased haptoglobin, which represents 
a typical acute phase plasma marker protein of tissue damage 
and the inflammatory response. The elevated concentration 
of haptoglobin was further investigated by immuno-labelling 
approaches, as outlined below. Besides serum haptoglobin, 
elevated levels of another acute phase plasma protein were 
established for amyloid A-1 protein (Table I).
Importantly, a variety of common serum markers of 
dystrophinopathy were verified by mass spectrometry 
(Tables I and II), including increased amounts of creatine 
kinase isoforms CK‑B, CK‑S and CK‑M, pyruvate kinase 
isoforms PKM and PKLR, hemopexin, adenylate kinase 
isoforms AK1 and AK2, carbonic anhydrase isoform CA3 and 
lactate dehydrogenase, which have been previously established 
by non-proteomic techniques (18-22). Elevated levels of previ-
ously identified proteomic serum markers were also confirmed 
(Tables I and II), such as fibronectin, coagulation factor V, 
titin, myosin light chain 1/3, fructose-bisphosphate aldolase 
(isoforms A-C), phosphoglucomutase (isoforms 1 and 2), 
enolase (isoforms α, β and γ), glycogen phosphorylase (muscle 
and liver isoforms), fatty acid-binding protein (adipocyte, 
epidermal, liver and heart isoforms), cytochrome c, malate 
Table II. List of previously established increased serum marker proteins that were also identified in 6‑month‑old mdx‑4cv mouse 
serum vs. age-matched wild-type mouse serum by label-free mass spectrometry.
Accession no. Protein name Unique peptides Confidence score Fold change
Q05816 Fatty acid-binding protein, epidermal  8 385.47 18.3
P13412 Troponin I, fast skeletal muscle  3 131.21 18.2
P62897 Cytochrome c, somatic  5 543.08 15.2
P05063 Fructose-bisphosphate aldolase C  9 679.32 14.8
P05977 Myosin light chain 1/3, skeletal muscle isoform  9 561.43 12.0
P52480 Pyruvate kinase PKM  46 4564.3 10.4
Q9ET01 Glycogen phosphorylase, liver form  36 2184.82 9.7
P12710 Fatty acid-binding protein, liver  11 928.62 8.4
Q04447 Creatine kinase B‑type  17 1492.20 8.2
P11499 Heat shock protein HSP 90-β  4 202.62 7.6
Q9WUB3 Glycogen phosphorylase, muscle form  48 4290.78 7.0
Q91Y97 Fructose‑bisphosphate aldolase B  20 1745.78 6.4
P17183 γ‑enolase  6 437.74 5.7
P08249 Malate dehydrogenase, mitochondrial  6 274.29 5.7
P20801 Troponin C, skeletal muscle  3 192.78 5.6
Q9D0F9 Phosphoglucomutase-1  22 1318.77 4.0
Q61316 Heat shock 70 kDa protein 4  20 1146.72 3.9
P53657 Pyruvate kinase PKLR  3 119.98 3.7
Q6P8J7 Creatine kinase S-type, mitochondrial  10 596.62 3.7
P14602 Heat shock protein β-1  3 150.33 3.3
P14152 Malate dehydrogenase, cytoplasmic  13 1108.02 3.3
P05064 Fructose-bisphosphate aldolase A  30 3015.5 3.1
P16125 L‑lactate dehydrogenase B chain  12 1000.89 2.9
P07901 Heat shock protein HSP 90-α  4 172.93 2.8
P17182 α-enolase  25 1951.59 2.7
P32848 Parvalbumin α  16 1096.30 2.6
P63017 Heat shock cognate 71 kDa protein  18 1479.96 2.5
P16015 Carbonic anhydrase 3  15 830.57 2.4
P07310 Creatine kinase M-type  30 2895.13 2.4
P11276 Fibronectin  6 298.37 2.3
P04117 Fatty acid-binding protein, adipocyte  9 800.82 2.2
Q9R0Y5 Adenylate kinase isoenzyme 1  3 247.3 2.2
O70250 Phosphoglucomutase 2  10 714.82 2.2
P21550 β-enolase  23 2090.28 2.1
P11404 Fatty acid-binding protein, heart  5 281.57 1.6
Q91X72 Hemopexin  32 2684.29 1.5
O88783 Coagulation factor V  6 223.63 1.3
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dehydrogenase (cytoplasmic and mitochondrial isoform), 
parvalbumin, troponin (muscle isoforms TnI and TnC) and 
various heat-shock proteins (HSP90-β, HSP90-α, HSP70, 
HSP β‑1, HSP cognate 71) (30‑39). These findings demon-
strate the reproducibility of the findings from a large number 
of biochemical and proteomic surveys of serum and plasma 
preparations from dystrophic patients and animal models of 
Duchenne muscular dystrophy.
The degree of decreased serum proteins was markedly 
less pronounced as compared to the increased protein species. 
Table III: List of decreased proteins in 6-month-old mdx‑4cv mouse serum vs. age-matched wild-type mouse serum exhibiting a 
fold-change above 2 as determined by label-free mass spectrometry.
Accession no. Protein name Unique peptides Confidence score Fold change
P09470 Angiotensin-converting enzyme  2 97.76 3.5
O35930 Platelet glycoprotein Ib α chain  11 865.35 3.4
Q07456 Protein AMBP  4 362.51 3.1
P28665 Murinoglobulin-1  116 12973.81 2.9
B5X0G2 Major urinary protein 17  5 231.6 2.8
Q00898 α-1-antitrypsin 1-5  14 1024.28 2.7
P05208 Chymotrypsin-like elastase family member 2A  3 230.49 2.7
O08742 Platelet glycoprotein V  5 601.56 2.6
Q03311 Cholinesterase  7 362.36 2.6
P01942 Hemoglobin subunit α  7 448.81 2.6
P42703 Leukemia inhibitory factor receptor  28 2444.33 2.5
Q62351 Transferrin receptor protein 1  5 278.54 2.5
Q9DBB9 Carboxypeptidase N subunit 2  15 1509.87 2.4
Q8QZR3 Pyrethroid hydrolase Ces2a  2 114.66 2.4
Q8BPB5 EGF‑containing fibulin‑like extracellular matrix protein 1  4 182.66 2.4
O88968 Transcobalamin-2  9 577.32 2.4
Q61704 Inter-α-trypsin inhibitor heavy chain H3  7 627.52 2.3
Q03734 Serine protease inhibitor A3M  9 788.27 2.3
E9Q414 Apolipoprotein B‑100  35 1947.84 2.3
Q07235 Glia-derived nexin  5 234.21 2.3
Figure 4. Summary of increased protein classes in mdx‑4cv mouse serum. The bioinformatic software programme PANTHER (56) was employed to establish 
the clustering of protein classes based on the mass spectrometric analysis of the albumin/IgG-depleted protein fraction from mdx‑4cv serum vs. wild-type 
serum (Tables I and II).
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Moderately reduced levels were shown to include angio-
tensin-converting enzyme, platelet glycoprotein Ib α chain, 
protein AMBP, murinoglobulin‑1, major urinary protein 17, 
α-1-antitrypsin 1-5, chymotrypsin-like elastase family member 
2A, platelet glycoprotein V, cholinesterase, hemoglobin 
subunit α, leukemia inhibitory factor receptor, transferrin 
receptor protein 1 and carboxypeptidase N subunit 2 (Table III). 
Figs. 4 and 5 show the bioinformatic PANTHER analysis of 
protein families (56) that were established to exhibit an altered 
concentration in mdx‑4cv mouse serum.
Figure 5. Summary of decreased protein classes in mdx‑4cv mouse serum. The bioinformatic software programme PANTHER (56) was employed to establish 
the clustering of protein classes based on the mass spectrometric analysis of the albumin/IgG-depleted protein fraction from mdx‑4cv serum vs. wild-type 
serum (Table III).
Figure 6. Immunoblot survey of proteins in mdx‑4cv mouse serum. Shown is a (A) silver-stained gel and corresponding immunoblots labelled with antibodies 
to (B) transferrin, (C) myoglobin, (D) parvalbumin, (E) LDH, (F) FABP‑1 and (G and H) HPG. HPG expression was evaluated with 2 different antibodies, 
(G) ab157714 and (H) ab131236. Lanes 1 and 2 represent crude serum from 6-month-old wild-type (wt) vs. dystrophic mdx‑4cv mice, respectively. Molecular 
mass standards are marked at the left of the panels. LDH, lactate dehydrogenase; FABP, fatty acid binding protein; HPG, haptoglobin. 
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Verification of proteomic profiling findings. Following the 
identification of a large number of altered serum proteins 
in the mdx‑4cv model of dystrophinopathy, we focused our 
study on the verification of a few key proteomic findings with 
a special emphasis on haptoglobin. Proteomic results were 
confirmed by immunoblotting and enzyme‑linked immuno-
sorbent assays with specific antibodies to a select number of 
serum proteins (Figs. 6-8). The immunoblot analysis of crude 
serum showed no significant changes in the abundance of 
serum transferrin, myoglobin and parvalbumin (Fig. 6B‑D). 
In contrast, lactate dehydrogenase and the FABP‑1 isoform of 
fatty acid binding protein exhibited elevated levels in crude 
mdx‑4cv serum (Figs. 6E and F). Most importantly, the highly 
increased concentration of serum haptoglobin in dystrophic 
mice, as shown by mass spectrometric analysis (Table I) was 
confirmed by immunoblotting with two different antibodies to 
this acute phase plasma protein (Fig. 6G and H). The statistical 
evaluation of immunoblotting is summarized in Fig. 7 and 
establishes the significant elvation of lactate dehydrogenase, 
fatty acid binding protein FABP‑1 and haptoglobin in crude 
mdx‑4cv serum.
In analogy to immunoblot analyses, enzyme-linked 
immunosorbent assays with antibodies to haptoglobin and 
FABP‑1 also showed increased levels of these two proteins 
in crude serum from dystrophic animals (Figs. 8B and C). 
Statistical ROC analyses demonstrated that these findings 
were highly significant (Figs. 8D and E). In contrast, values 
for complement C3 were found to be comparable between 
wild-type and mdx‑4cv serum (Fig. 8A).
Discussion
A key step in the molecular pathogenesis of X-linked 
muscular dystrophy is mediated by the disintegration of the 
dystrophin-glycoprotein complex (4) resulting in sarcolemmal 
destabilisation, impaired cellular signalling, abnormal ion 
fluxes and increased proteolysis (6). This primary mechanism 
of fibre damage is accompanied by adaptive responses, such as 
myofibrosis (10), and secondary changes related to an inflam-
matory pathology (16). In addition to massive proteome-wide 
changes within skeletal muscle fibres (46,50‑52,60,72‑74), the 
deficiency in dystrophin isoform Dp427 also causes substantial 
alterations in the rate of protein release from muscle tissues into 
the circulatory system and other plasma fluctuations (30‑39). 
This includes actively secreted proteins and passively released 
components from mechanically damaged fibres and other 
types of tissue (29). In this respect, one of the major findings of 
the proteomic serum study presented here is the identification 
of elevated haptoglobin levels in mdx‑4cv serum by mass spec-
trometry, immunoblotting and enzyme-linked immunosorbent 
assays.
This acute phase plasma protein is a tissue damage 
marker and is often increased in serum in relation to cellular 
degeneration and inflammation (75). Since there is an urgent 
need to establish new biomarker candidates of X-linked 
muscular dystrophy (76), the proteomic identification 
of elevated haptoglobin levels in dystrophinopathy is an 
encouraging result. Haptoglobin, in conjunction with other 
altered serum proteins, may represent a novel diagnostic, 
Figure 7. Significant changes of proteins in the mdx‑4cv mouse serum. Shown is the graphical presentation of the statistical evaluation of the immunoblots 
depicted in Fig. 6. The comparative blotting between crude serum samples from 6-month-old wild-type (wt) vs. mdx‑4cv mice was statistically evaluated 
using an unpaired Student's t‑test (n=4; *P<0.05, **P<0.01, ***P<0.001). Shown is the analysis of (A) transferrin, (B) myoglobin, (C) parvalbumin, (D) LDH,  (E) 
FABP‑1, and (F and G) HPG. LDH, lactate dehydrogenase; FABP, fatty acid binding protein; HPG, haptoglobin.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE  39:  1357-1370,  2017 1367
prognostic and/or therapy-monitoring biomarker candidate 
for the improved evaluation of sterile inflammation in the 
mdx‑4cv animal model of dystrophinopathy. Haptoglobin is 
a major acute phase plasma protein that acts as a high‑affinity 
hemoglobin-binding protein and protective anti-oxidant (77). 
The liver is the main site of haptoglobin synthesis, but this 
protein is also produced in other organs (43). The increased 
serum haptoglobin levels established here by mass spectrometry 
agree with a pre-proteomic analysis by two-dimensional 
gel electrophoresis and densitometric scanning by John and 
Purdom (78). A recent serum proteomic profiling study by 
Rouillon et al (37) with a focus on the characterization of the 
myofibrillar structural protein myomesin isoform MYOM3 
also identified haptoglobin as a potential biomarker candidate 
for monitoring the outcome of therapeutic interventions in 
Duchenne muscular dystrophy.
The cellular disturbances and multi-system pathology of 
dystrophinopathy are closely associated with highly complex 
and interconnecting damage pathways, including modifying 
factors such as abnormal Ca2+ flux, increased proteolytic 
degradation, elevated extracellular ATP levels and altered 
cytokine signalling (6,8). In addition to promoting hyperac-
tive extracellular matrix remodelling and resulting fibrotic 
scarring, these processes stimulate harmful inflammatory 
responses (79). Macrophages are intrinsically involved in both 
the natural repair of acutely injured skeletal muscle fibres and 
the pathological exacerbation of chronically damaged contrac-
tile cells (80). Inflammatory monocyte‑derived macrophages 
appear to be closely associated with disturbed chemokine 
levels and are key cell types that promote changes in dystro-
phin-deficient and degenerating skeletal muscles (13,81). 
Sterile tissue injury that occurs chronically in muscular 
dystrophy initiates a local inflammatory response. This in turn 
triggers the mobilization of the acute phase reaction causing a 
massive increase in the level of acute phase plasma proteins in 
the circulatory system.
As a biomarker of dystrophinopathy, the advantages 
of serum haptoglobin are manifold as compared to 
muscle-associated proteins, since the application of diagnostic 
or prognostic biomarkers associated with the skeletal muscle 
interior would require the undesirable usage of invasive 
methodology (62). In contrast, the systematic mining of the 
biofluid proteome promises to identify novel marker molecules 
that can be assayed in a minimally invasive or non-invasive 
manner and may also result in the proteomic identification of 
new therapeutic targets (82-84). However, it is important to 
emphasise that the field of predictive and diagnostic medicine 
has had only limited success in the translation from biomarker 
discovery to clinical utility, especially in relation to biomarker 
specificity (85). This would also be a critical issue in the future 
application of haptoglobin as a biomarker, since this serum 
protein was recently identified as a novel marker molecule, 
which is potentially suitable for predicting a variety of human 
diseases including colorectal cancer hepatic metastasis (86).
In the case of muscular dystrophy, one can assume that 
damaged and leaky skeletal muscle tissue has an enhanced 
tendency to actively release or passively shed proteins, 
metabolites and other biomolecules into their external 
environment. These factors also trigger secondary changes in 
other tissue and organ systems in the body and thereby cause 
considerable plasma fluctuations. The range and density of 
released protein species relates relatively well to the degree 
of cellular damage (29). In addition to the effects on acute 
phase plasma protein concentration, this proteomic study has 
Figure 8. Enzyme‑linked immunosorbent assays. Shown are the findings from enzyme‑linked immunosorbent assays of crude serum samples that were 
screened with antibodies to: (A) complement C3, (B) HPG and (C) FABP‑1. Statistical analyses using (B and C) the Mann‑Whitney U test (wt serum samples: 
n=4; mdx‑4cv serum samples: n=8; **P≤0.01 and (D and E) statistical ROC curve analyses demonstrated that the increases in (B and D) HPG and (C and E) 
FABP‑1 in mdx‑4cv serum were highly significant. HPG. haptoglobin; FABP, fatty acid binding protein; ROC, receiver operating characteristic.
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shown that highly complex proteome-wide alterations occur 
in the serum in a dystrophic organism. As established by the 
systems bioinformatic analysis of the proteomic mdx‑4cv 
serum data (56), affected protein families include cytoskeletal 
proteins, hydrolases, oxidoreductases, transferases, nucleic acid 
binding proteins, molecular chaperones, proteases, signalling 
molecules and ion-handling proteins. These proteins with an 
altered serum concentration are involved in many complex 
cellular activities, such as energy metabolism, physiological 
regulation, fibre adaptations, intercellular and intracellular 
signalling, the stress response, fibre transitions and the 
excitation‑contraction‑relaxation cycle. The proteomic findings 
emphasize the pathobiochemical complexity of the dystrophic 
phenotype and suggest that future therapeutic approaches have 
to address a variety of downstream changes from the primary 
abnormality in the membrane cytoskeleton (3).
In conclusion, the identification of robust and unambiguous 
biomarkers of high biomedical and clinical value is an 
important aim of the systematic assessment of pathological 
specimens related to X-linked muscular dystrophy. Here, we 
identified elevated levels of the acute phase plasma protein 
haptoglobin in the serum from dystrophic mdx‑4cv mice 
as a new potential indicator molecule of the inflammatory 
phenotype of dystrophinoapthy. Since antibody-based tests 
have confirmed the significantly increased concentration of 
serum haptoglobin, this protein represents a solid biomarker 
candidate. Haptoglobin is easily assessable, exhibits a high 
diagnostic potential and has suitable physicochemical 
properties. Hence, this serum protein is an ideal candidate 
molecule for the future establishment of a sensitive and 
cost‑effective test system to evaluate inflammatory processes 
related to skeletal muscle damage in muscular dystrophy.
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